Filling method of phloroglucinol injection

By introducing pressurized carbon dioxide into the phthalocyanol injection to form carbonic acid and decompose it, the problem of difficult to reduce residual oxygen during the filling process is solved, a lower oxygen content is achieved, and product quality is improved.

CN118907507APending Publication Date: 2024-11-08SICHUAN KELUN PHARMA CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411249788.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The residual oxygen level during the filling process of the existing phlogenes injection is difficult to further reduce, and there are technical difficulties.

Method used

Before filling, pressurized carbon dioxide gas is introduced into the phlogenesol injection to form carbonic acid, and it is decomposed in subsequent filling equipment, releasing a large amount of carbon dioxide, thereby preventing oxygen from entering the ampoule and reducing residual oxygen .

Benefits of technology

Through this method, the residual oxygen amount of phlogenetic injection dropped to 0.1 to 0.2% during non-destructive testing and to 0.4 to 0.5% during destructive testing, solving the technical problem that the residual oxygen amount cannot be further reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118907507A_ABST
    Figure CN118907507A_ABST
Patent Text Reader

Abstract

The invention discloses a filling method of phloroglucinol injection, which comprises the following steps: after the phloroglucinol injection is prepared, carbon dioxide is introduced into the phloroglucinol injection to form carbonic acid, then the injection flows into subsequent filling equipment, the carbon dioxide is pressurized gas, and the pressure of the pressurized carbon dioxide is 0.1-0.2 Mpa. According to the method, pressurized carbon dioxide gas is introduced into the phloroglucinol injection before filling to form carbonic acid, and carbonic acid in the injection in subsequent filling equipment is decomposed to release a large amount of carbon dioxide, so that the residual oxygen content in the phloroglucinol injection is greatly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of filling of phloroglucinol injection, and particularly relates to a filling method of phloroglucinol injection. Background Art

[0002] Phloroglucinol (1,3,5-trihydroxybenzene) is an important fine chemical product, mainly used as an intermediate for drug synthesis, such as flavonoid compounds. Phloroglucinol is currently widely used in clinical antispasmodic analgesics for acute spasmodic pain caused by digestive system and biliary dysfunction; acute spasmodic urethral, ​​bladder, and renal colic; and gynecological spasmodic pain. It is a pure smooth muscle antispasmodic drug that is not atropine or opium poppy alkaloid. It has little effect on normal smooth muscle and acts directly on spasmodic smooth muscle.

[0003] Phloroglucinol injection was launched in France in January 1993. The dosage form is injection, the specification is: 4ml: 40mg, the trade name is Spasfon, and the licensee is TevaSante.

[0004] Phloroglucinol is a white or off-white crystalline powder that is slightly soluble in water. After the preparation, the phloroglucinol injection needs to be filled into an ampoule for subsequent injection application. When filling the existing phloroglucinol, it is first prepared according to the process requirements, and then filtered and accurately measured into the ampoule. In order to improve the quality of phloroglucinol and prevent oxygen from entering the ampoule during the filling process, carbon dioxide will be pre-filled into the ampoule before and after filling, and finally carbon dioxide will be filled into the ampoule during the sealing process to complete the filling. The purpose of this setting is to reduce the retention of oxygen in the ampoule and reduce the residual oxygen content. The residual oxygen content in the phloroglucinol injection on the market is generally between 0.4 and 0.5% during non-destructive testing, and generally between 0.8 and 0.9% during destructive testing. If you want to further reduce the residual oxygen content, it cannot be obtained, and there are great technical difficulties.

[0005] In view of this, this patent application is filed. Summary of the invention

[0006] The purpose of this patent application is to solve the technical problem that the residual oxygen content in the existing filled phloroglucinol injection cannot be further reduced, and a filling method for phloroglucinol injection is provided. Before filling, pressurized carbon dioxide gas is introduced into the phloroglucinol injection to form carbonic acid. In the subsequent filling equipment, the carbonic acid in the injection is decomposed to release a large amount of carbon dioxide, thereby significantly reducing the residual oxygen content in the phloroglucinol injection.

[0007] The present invention is achieved through the following technical solutions:

[0008] The object of the present invention is to provide a filling method for phloroglucinol injection. After the phloroglucinol injection is prepared, carbon dioxide is introduced into the phloroglucinol injection to form carbonic acid, and then the injection is allowed to flow into subsequent filling equipment. The carbon dioxide is a pressurized gas, and the pressure of the pressurized carbon dioxide is 0.1-0.2Mpa.

[0009] In the embodiment of the present invention, the filling method provided is to introduce carbon dioxide into the prepared phloroglucinol injection before filling, and the carbon dioxide gas is a pressurized gas, so that the carbon dioxide is dissolved in the injection water, and a large amount of carbonic acid can be formed in the phloroglucinol injection. When the phloroglucinol injection flows into the subsequent filling equipment, the injection will form a pressure loss situation. At this time, the carbonic acid in the phloroglucinol injection will decompose and release a large amount of carbon dioxide, thereby preventing oxygen from entering the ampoule when filling into the ampoule and sealing, and squeezing the oxygen in the ampoule out, thereby significantly reducing the residual oxygen content in the phloroglucinol injection.

[0010] In an optional embodiment, the pressure of the pressurized carbon dioxide is 0.15 MPa. The use of pressurized carbon dioxide at this pressure can maintain a stable dissolved amount of carbon dioxide in the injection solution, thereby ensuring the stable release of carbon dioxide in the subsequent process of carbonic acid and ensuring the stable performance of the product.

[0011] In an optional embodiment, pressurized carbon dioxide is introduced into the phloroglucinol injection for 25 to 35 minutes to form carbonic acid. The pressurized carbon dioxide is introduced for 25 to 35 minutes in the present invention to allow the carbon dioxide to fully react in the injection to ensure the stability of the obtained filled phloroglucinol injection.

[0012] In an alternative embodiment, pressurized carbon dioxide is introduced into the phloroglucinol injection solution for 30 minutes to form carbonic acid.

[0013] In an optional embodiment, phloroglucinol is prepared in a preparation tank, and pressurized carbon dioxide is introduced from the bottom of the preparation tank to allow the carbon dioxide to contact the injection solution more fully.

[0014] In an optional embodiment, the pressurized carbon dioxide is continuously introduced into the preparation tank when the preparation tank is opened to allow the injection to flow into the subsequent filling equipment. The design purpose is to ensure that the phloroglucinol injection still maintains sufficient pressure when it flows out of the preparation tank, avoid pressure loss in the phloroglucinol injection, and maintain a sufficient concentration of carbonic acid.

[0015] In an optional embodiment, the pressure of pressurized carbon dioxide that continues to be introduced into the preparation tank when the injection liquid flows into the subsequent filling equipment is 0.15 MPa.

[0016] In an optional embodiment, pressurized carbon dioxide is introduced from the top of the preparation tank to pressure-feed the phloroglucinol injection to the subsequent filling equipment. In the embodiment of the present invention, the injection is pressure-feeded from the top of the preparation tank with the same pressure, so that the pressure of 0.15MP is always maintained before the buffer tank, ensuring that no pressure release occurs before entering the buffer tank, and ensuring that sufficient carbon dioxide is generated when filling into the ampoule bottle.

[0017] In an optional embodiment, the injection liquid in the preparation tank is filtered and then sequentially enters the buffer tank and the liquid distributor. When the injection liquid in the buffer tank reaches the upper limit and the machine is stopped, the injection liquid in the connecting pipe between the buffer tank and the liquid distributor is discarded and discharged. This is because this part of the liquid medicine may be discharged due to the decomposition of carbonic acid to generate carbon dioxide, which loses the effect of preventing the entry of oxygen in the subsequent filling and drawing.

[0018] In an optional embodiment, the injection liquid from the liquid dispenser is poured into a plurality of ampoules respectively, and each ampoule is filled with carbon dioxide before filling, each ampoule is filled with carbon dioxide after filling with the injection liquid, filled with carbon dioxide during the sealing wire drawing preheating, and filled with carbon dioxide during the wire drawing sealing. The pressure of the carbon dioxide filled in the ampoule is lower than the pressure of the carbon dioxide filled in the preparation tank. It is better to use 0.02MPa of carbon dioxide filled before filling, after filling, during the sealing wire drawing preheating, and during the wire drawing sealing, which can prevent oxygen from entering the ampoule; prevent the liquid medicine from being blown and splashed to affect the filling amount; and do not affect the wire drawing sealing effect.

[0019] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0020] (1) The filling method provided in the embodiment of the present invention introduces pressurized carbon dioxide gas into the phloroglucinol injection before filling, so that the carbon dioxide is dissolved in the injection water, and a large amount of carbonic acid can be formed in the phloroglucinol injection. When the phloroglucinol injection flows into the subsequent filling equipment, the injection will form a pressure loss situation. At this time, the carbonic acid in the phloroglucinol injection will decompose and release a large amount of carbon dioxide, thereby preventing oxygen from entering the ampoule when filling into the ampoule and sealing, and squeezing the oxygen in the ampoule out, thereby greatly reducing the residual oxygen content in the phloroglucinol injection.

[0021] (2) The filling method provided by the present invention fills carbon dioxide into the ampoule bottle before filling, after filling, during the sealing wire drawing preheating, and during the wire drawing sealing, so as to further reduce the residual oxygen content.

[0022] (3) The residual oxygen content of the filled phloroglucinol injection obtained by the filling method of the present invention is 0.1-0.2% in non-destructive testing and 0.4-0.5% in destructive testing. Compared with the residual oxygen content of the phloroglucinol injection obtained by the prior art, which is 0.3%-0.5% lower under destructive testing, the technical difficulty of being unable to further reduce the residual oxygen content is solved. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions of the exemplary embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and should not be regarded as limiting the scope. For those of ordinary skill in the art, other relevant drawings can be obtained based on these drawings without creative work. In the drawings:

[0024] Figure 1 This is a schematic diagram of the structure of the filling device used in the filling method of the present invention.

[0025] The accompanying drawings and corresponding symbols are:

[0026] 1- preparation tank, 2- filter, 3- buffer tank, 4- dispenser, 5- ceramic pump, 6- filling process station. DETAILED DESCRIPTION

[0027] The following embodiments further describe the implementation of the present application in detail. The detailed description of the following embodiments is used to illustrate the principle of the present application, but cannot be used to limit the scope of the present application, that is, the present application is not limited to the described embodiments.

[0028] The "range" disclosed in the present application is defined in the form of a lower limit and an upper limit, and a given range is defined by selecting a lower limit and an upper limit, and the selected lower limit and upper limit define the boundaries of the particular range. The range defined in this way can be inclusive or exclusive of the end values, and can be arbitrarily combined, that is, any lower limit can be combined with any upper limit to form a range. For example, if a range of 60 to 120 and 80 to 110 is listed for a particular parameter, it is understood that a range of 60 to 110 and 80 to 120 is also expected. In addition, if the minimum range values ​​1 and 2 are listed, and if the maximum range values ​​3, 4 and 5 are listed, the following ranges can all be expected: 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4 and 2 to 5. In the present application, unless otherwise specified, the numerical range "a to b" represents an abbreviation of any real number combination between a and b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" are listed in this document, and "0-5" is just an abbreviation of these numerical combinations. In addition, when a parameter is expressed as an integer ≥ 2, it is equivalent to disclosing that the parameter is, for example, an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.

[0029] Unless otherwise specified, all embodiments and optional embodiments of the present application can be combined with each other to form a new technical solution.

[0030] Unless otherwise specified, all technical features and optional technical features of this application can be combined with each other to form a new technical solution.

[0031] If there is no special explanation, all steps of the present application can be performed sequentially or randomly, preferably sequentially. For example, the method includes steps (a) and (b), which means that the method may include steps (a) and (b) performed sequentially, or may include steps (b) and (a) performed sequentially. For example, the method may further include step (c), which means that step (c) may be added to the method in any order. For example, the method may include steps (a), (b) and (c), or may include steps (a), (c) and (b), or may include steps (c), (a) and (b), etc.

[0032] If there is no special explanation, the "include" and "comprising" mentioned in this application represent open-ended or closed-ended expressions. For example, the "include" and "comprising" may represent that other components not listed may also be included or only the listed components may be included or only the listed components may be included.

[0033] If not specifically stated, in this application, the term "or" is inclusive. For example, the phrase "A or B" means "A, B, or both A and B". More specifically, any of the following conditions satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist); A is false (or does not exist) and B is true (or exists); or both A and B are true (or exist).

[0034] Embodiment 1:

[0035] The filling method of the present invention is as follows Figure 1 The filling device is carried out, specifically including a preparation tank 1, a filter 2, a buffer tank 3, a liquid distributor 4, a ceramic pump 5, and a filling process station 6.

[0036] The preparation tank 1 is provided with two gas pipelines, one pipeline leading to the bottom of the preparation tank 1 and the other leading to the top of the preparation tank 1, and is provided with corresponding valves.

[0037] The phloroglucinol injection product is prepared in the preparation tank 1 according to the process requirements. The preparation process includes replacing the oxygen in the preparation tank 1 with carbon dioxide gas and protecting the phloroglucinol injection with carbon dioxide. After the preparation is completed, carbon dioxide is introduced from the bottom of the preparation tank 1. The introduced carbon dioxide is pressurized to 0.15MPa and the pressurized carbon dioxide is continuously introduced for 30 minutes to form a large amount of carbonic acid in the injection. Then, the injection is pressed out of the preparation tank 1 to the filter 2 and subsequent equipment using pressurized carbon dioxide 0.15MPa from the top of the preparation tank 1.

[0038] The filter 2 can be designed in multiple numbers, such as 4, to form a four-stage filtration to filter impurities in the product and enter the buffer tank 3.

[0039] The buffer tank 3 can cooperate with the ceramic pump 5 of the filling machine to accurately measure and fill, and at the same time, carbon dioxide enters from the bottom of the buffer tank 3 to the top thereof for oxygen removal protection.

[0040] The dispenser 4 is used to automatically distribute the phloroglucinol injection solution into each ceramic pump 5 .

[0041] The ceramic pump 5 is used to accurately measure the filling volume of each product, and multiple ceramic pumps 5, such as 8, may be provided.

[0042] There are 5 filling process stations 6. The first station is used to discharge the air (oxygen) in the empty bottle, and serves as the carbon dioxide flushing station for the empty bottle; the second station is responsible for filling, and serves as the filling station; the third station is responsible for replacing the residual oxygen on the upper end of the medicine liquid, and serves as the post-filling carbon dioxide filling station; the fourth station is responsible for preheating the ampoule bottle, and at the same time replacing the residual oxygen on the upper end of the medicine liquid, and serves as the preheating carbon dioxide filling station; the fifth station is responsible for replacing the residual oxygen on the upper end of the medicine liquid, and at the same time drawing and melting the product, and serves as the drawing, sealing and carbon dioxide filling station.

[0043] After the preparation, the injection liquid is pressed with carbon dioxide to deliver the phloroglucinol injection liquid, which reaches the buffer tank 3 after four-stage filtration. When the amount of phloroglucinol in the buffer tank 3 reaches the upper limit, the automatic valve at the front end of the buffer tank 3 is closed. Since the amount of phloroglucinol injection product in the connecting pipeline between the buffer tank 3 and the liquid distributor 4 is not large, the filling is completed quickly. If the machine is stopped halfway, the phloroglucinol liquid in the connecting pipeline between the buffer tank 3 and the liquid distributor 4 should be discharged, so the discharge amount needs to be calculated. Under the action of the ceramic pump 5, the liquid passes through the liquid distributor 4, the ceramic pump 5 and related pipelines, and is respectively filled into the ampoule bottle through the filling needle of the filling machine; the bottle is installed at the front end of the filling machine, and it passes through the five stations of pre-charging with carbon dioxide, filling, filling with carbon dioxide after filling, preheating and charging with carbon dioxide, and drawing and sealing to charge with carbon dioxide. Finally, the product is sent out of the filling machine through the relevant mechanism. When filling carbon dioxide at each station, 0.02MPa carbon dioxide is used to prevent oxygen from entering the ampoule bottle; prevent the liquid medicine from splashing and affecting the filling volume; and do not affect the wire drawing and sealing effect.

[0044] Embodiment 2:

[0045] In this embodiment, Figure 1 The filling device is used in the filling process.

[0046] The difference from Example 1 is that after the preparation is completed, carbon dioxide is introduced from the bottom of the preparation tank 1, and the introduced carbon dioxide is pressurized to 0.10 MPa, and the pressurized carbon dioxide is continuously introduced for 30 minutes to form a large amount of carbonic acid in the injection. Then, the injection is pressed out of the preparation tank 1 to the filter 2 and subsequent equipment using pressurized carbon dioxide 0.10 MPa from the top of the preparation tank 1.

[0047] The rest are the same as in Example 1.

[0048] Embodiment 3:

[0049] In this embodiment, Figure 1 The filling device is used in the filling process.

[0050] The difference from Example 1 is that after the preparation is completed, carbon dioxide is introduced from the bottom of the preparation tank 1, and the introduced carbon dioxide is pressurized to 0.20 MPa. The pressurized carbon dioxide is continuously introduced for 30 minutes to form a large amount of carbonic acid in the injection. Then, the injection is pressed out of the preparation tank 1 to the filter 2 and subsequent equipment using pressurized carbon dioxide 0.20 MPa from the top of the preparation tank 1.

[0051] Embodiment 4:

[0052] In this embodiment, Figure 1 The filling device is used in the filling process.

[0053] The difference from Example 1 is that after the preparation is completed, carbon dioxide is introduced from the bottom of the preparation tank 1, and the introduced carbon dioxide is pressurized to 0.15 MPa. The pressurized carbon dioxide is continuously introduced for 25 minutes to form a large amount of carbonic acid in the injection. Then, the injection is pressed out of the preparation tank 1 to the filter 2 and subsequent equipment using pressurized carbon dioxide 0.15 MPa from the top of the preparation tank 1.

[0054] The residual oxygen content of the products obtained in Examples 1 to 4 was measured, and the impurity content after different time periods was measured. The specific results are shown in Table 1 below:

[0055] Table 1

[0056]

[0057] The inventors continued to use the filling method of Example 1 to conduct a pilot test and obtained the measurement results of different batches. The results are shown in Table 2:

[0058] Table 2

[0059]

[0060]

[0061] The inventors also compared the case where no pressurized carbon dioxide was introduced before filling, and the data obtained were shown in Table 3:

[0062] Table 3

[0063]

[0064] According to the above results, it can be seen that the residual oxygen content of the pilot test results of the phloroglucinol injection obtained by the filling method of the present invention is about 0.4% lower than that of the previous product, and the relevant performance indicators are significantly improved.

[0065] The filled phloroglucinol injection obtained by the filling method of the present invention has a residual oxygen content of 0.1-0.2% during non-destructive testing and a residual oxygen content of 0.4-0.5% during destructive testing, which is 0.3%-0.5% lower than the residual oxygen content of the phloroglucinol injection obtained by the prior art under destructive testing, thus solving the current technical difficulty of being unable to further reduce the residual oxygen content.

[0066] The above specific implementation methods further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific implementation methods of the present invention and are not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A filling method for phloroglucinol injection, characterized in that: After the preparation of the phloroglucinol injection is completed, carbon dioxide is introduced into the phloroglucinol injection to form carbonic acid, and then the injection is allowed to flow into subsequent filling equipment. The carbon dioxide is a pressurized gas, and the pressure of the pressurized carbon dioxide is 0.1-0.2 MPa.

2. The filling method of phloroglucinol injection according to claim 1, characterized in that: The pressure of the pressurized carbon dioxide is 0.15 MPa.

3. The filling method of phloroglucinol injection according to claim 1, characterized in that: Pressurized carbon dioxide is passed into the phloroglucinol injection for 25 to 35 minutes to form carbonic acid.

4. The filling method of phloroglucinol injection according to claim 1, characterized in that: Pressurized carbon dioxide was bubbled into the phloroglucinol injection solution for 30 minutes to form carbonic acid.

5. A filling method for phloroglucinol injection according to any one of claims 1 to 4, characterized in that: Phloroglucinol is prepared in a preparation tank, and pressurized carbon dioxide is introduced from the bottom of the preparation tank.

6. The filling method of phloroglucinol injection according to claim 1, characterized in that: Continue to introduce pressurized carbon dioxide into the preparation tank while opening the preparation tank to allow the injection solution to flow into the subsequent filling equipment.

7. The filling method of phloroglucinol injection according to claim 6, characterized in that: When the injection solution flows into the subsequent filling equipment, the pressure of pressurized carbon dioxide continued to be introduced into the preparation tank at 0.15MPa.

8. A filling method for phloroglucinol injection according to claim 6 or 7, characterized in that: Pressurized carbon dioxide is introduced from the top of the preparation tank to pressure-transfer the phloroglucinol injection to the subsequent filling equipment.

9. The filling method of phloroglucinol injection according to claim 1, characterized in that: The injection liquid in the preparation tank is filtered and then enters the buffer tank and the dispenser in turn. When the injection liquid in the buffer tank reaches the upper limit and the machine is shut down, the injection liquid in the connecting pipe between the buffer tank and the dispenser is discarded and discharged.

10. The filling method of phloroglucinol injection according to claim 1, characterized in that: The injection liquid coming out of the dispenser is poured into multiple ampoules respectively. Each ampoule is filled with carbon dioxide before filling, each ampoule is filled with carbon dioxide after filling with the injection liquid, filled with carbon dioxide during the preheating of the sealing wire drawing, and filled with carbon dioxide during the wire drawing and sealing. The pressure of the carbon dioxide filled in the ampoule is 0.02MPa; Preferably, during the process of pouring the injection solution into each ampoule, the exposure time of the phloroglucinol injection solution is less than 10.7 seconds.

Citation Information

Patent Citations

  • Medicine solution filling system

    CN111777012A

  • Phloroglucinol injection and preparation method thereof

    CN112516077A

  • Preparation method of phloroglucinol injection

    CN114948865A

  • Ampoule wiredrawing and filling machine

    CN116462145A

  • Preparation method and application of phloroglucinol injection

    CN117942301A